Evaluation of Cemiplimab in Combination With Platinum-Doublet Chemotherapy in First-Line (1L) Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) in Adult United States (US) Patients
This multi-year cohort study will assess the real-world safety and effectiveness of 1L treatment with cemiplimab in combination with platinum-doublet chemotherapy across advanced NSCLC patient subgroups defined by age, sex, race, and ethnicity. Patients will be retrospectively identified from at least two US electronic health record (EHR)-based databases.
Checked against the public recordLast updated May 8, 2026 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Not specified
- Study type
- Observational
- Phase
- Not applicable
- Sponsor
- Regeneron Pharmaceuticals
- Interventions being studied
- Drug: REGN2810; Other: Platinum-doublet chemotherapy
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Key Inclusion Criteria: 1\. Advanced non-small cell lung cancer (aNSCLC) (defined as stage IIIB/C or stage IV) treated with cemiplimab in combination with platinum-doublet chemotherapy in the 1L setting from Nov 2022 to Jun 2026 as described in the protocol Key Exclusion Criteria: 1. Patients who have EGFR, ALK or ROS1 variants 2. Treatment with EGFR, ALK or ROS1 inhibitors at any time prior to the index date 3. Patients actively enrolled in a clinical trial in which they receive treatment with cemiplimab in combination with platinum-doublet chemotherapy Note: Other protocol-defined Inclusion/ Exclusion Criteria apply
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Regeneron Research FacilityTarrytown, New York
Source and freshness
Processed from ClinicalTrials.gov. Last public update: May 8, 2026. Always confirm current availability with the study team.